This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01180/identifier/pubchem-substance/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01180/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01180/identifier/drugbank/
n15http://linked.opendata.cz/resource/mesh/concept/
n10http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB01180/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n4http://linked.opendata.cz/resource/drugbank/drug/DB01180/identifier/chebi/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/ontology/mesh/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01180/identifier/wikipedia/
n5http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01180/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01180/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01180/identifier/pubchem-compound/
n19http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01180
rdf:type
n5:Drug
n5:description
Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from <i>Rauwolfia serpentina</i> and other species of <i>Rauwolfia</i>. [Wikipedia]
n5:group
approved
n5:indication
For the treatment of hypertension.
owl:sameAs
n10:DB01180 n13:DB01180
dcterms:title
Rescinnamine
adms:identifier
n4:28572 n7:30295 n11:5280954 n12:46507786 n16:Rescinnamine n17:PA164768818 n20:D00198 n21:DB01180 n22:C06540
n5:mechanismOfAction
Rescinnamine Binds to and inhibits the angiotensin converting enzyme. Rescinnamine competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion.
n5:synonym
3,4,5-Trimethoxycinnamoyl methyl reserpate Rescinnamine Tsuruselpi S Trimethoxy cinnamoyl reserpate de methyl
n14:hasConcept
n15:M0225306
n5:IUPAC-Name
n6:271B4FB9-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4FBF-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4FBE-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4FBB-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4FBC-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4FBD-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4FB7-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4FD0-363D-11E5-9242-09173F13E4C5 n6:271B4FB5-363D-11E5-9242-09173F13E4C5 n6:271B4FB8-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4FB6-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:C02AA01
n5:H-Bond-Acceptor-Count
n6:271B4FC5-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4FC6-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4FC0-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4FC1-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4FC3-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4FC2-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4FC4-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
24815-24-5
n5:Bioavailability
n6:271B4FCB-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4FCD-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4FCE-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B4FCF-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4FCA-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4FC9-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4FCC-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4FBA-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4FC7-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4FC8-363D-11E5-9242-09173F13E4C5